HK1254859A1 - 治疗乳腺癌的方法 - Google Patents

治疗乳腺癌的方法 Download PDF

Info

Publication number
HK1254859A1
HK1254859A1 HK18113956.5A HK18113956A HK1254859A1 HK 1254859 A1 HK1254859 A1 HK 1254859A1 HK 18113956 A HK18113956 A HK 18113956A HK 1254859 A1 HK1254859 A1 HK 1254859A1
Authority
HK
Hong Kong
Prior art keywords
entinostat
exemestane
treatment
level
protein lysine
Prior art date
Application number
HK18113956.5A
Other languages
English (en)
Chinese (zh)
Inventor
R‧古德诺
R‧古德諾
P‧奥登特里科
P‧奧登特里科
Original Assignee
辛达克斯制药股份有限公司
辛達克斯製藥股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47756940&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1254859(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 辛达克斯制药股份有限公司, 辛達克斯製藥股份有限公司 filed Critical 辛达克斯制药股份有限公司
Publication of HK1254859A1 publication Critical patent/HK1254859A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/4833—Physical analysis of biological material of solid biological material, e.g. tissue samples, cell cultures
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Optics & Photonics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
HK18113956.5A 2011-09-02 2018-11-01 治疗乳腺癌的方法 HK1254859A1 (zh)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201161530873P 2011-09-02 2011-09-02
US61/530,873 2011-09-02
US201161532534P 2011-09-08 2011-09-08
US61/532,534 2011-09-08
US201161628999P 2011-11-12 2011-11-12
US61/628,999 2011-11-12
US201161568110P 2011-12-07 2011-12-07
US61/568,110 2011-12-07

Publications (1)

Publication Number Publication Date
HK1254859A1 true HK1254859A1 (zh) 2019-07-26

Family

ID=47756940

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18113956.5A HK1254859A1 (zh) 2011-09-02 2018-11-01 治疗乳腺癌的方法

Country Status (15)

Country Link
US (2) US10226472B2 (enExample)
EP (2) EP2751267B1 (enExample)
JP (2) JP6195384B2 (enExample)
KR (1) KR101956861B1 (enExample)
CN (3) CN107982270A (enExample)
AU (2) AU2012301616B2 (enExample)
BR (1) BR112014005080A2 (enExample)
CA (1) CA2847348A1 (enExample)
EA (1) EA201201474A1 (enExample)
ES (1) ES2663407T3 (enExample)
GE (1) GEP201706612B (enExample)
HK (1) HK1254859A1 (enExample)
MX (1) MX358254B (enExample)
UA (6) UA123212U (enExample)
WO (1) WO2013033656A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA123212U (uk) 2011-09-02 2018-02-26 Общєство С Огранічєной Отвєтствєностью "Новамедіка" Спосіб лікування раку молочної залози
CN105492007A (zh) * 2013-05-03 2016-04-13 欣达克斯制药公司 癌症治疗方法
US20180104232A1 (en) * 2015-03-12 2018-04-19 The University Of Chicago Methods for determining prognosis for breast cancer patients
EP3345002A4 (en) * 2015-09-02 2019-05-08 Syndax Pharmaceuticals Inc. SELECTION OF PATIENTS FOR COMBINATION THERAPY
EP4650005A2 (en) 2016-07-15 2025-11-19 Viracta Subsidiary, Inc. Histone deacetylase inhibitors for use in immunotherapy
WO2018016563A1 (en) * 2016-07-20 2018-01-25 Eisai R&D Management Co., Ltd. Use of eribulin and histone deacetylase inhibitors in the treatment of cancer
CA3063718A1 (en) 2017-05-19 2018-11-22 Syndax Pharmaceuticals, Inc. Combination therapies
CA3099702A1 (en) 2018-05-07 2019-11-14 Syndax Pharmaceuticals, Inc. Selection of patients for combination therapy
KR102212699B1 (ko) 2019-08-12 2021-02-05 한국원자력의학원 유방암 예방 또는 치료용 조성물
US12017506B2 (en) 2020-08-20 2024-06-25 Denso International America, Inc. Passenger cabin air control systems and methods
US12377711B2 (en) 2020-08-20 2025-08-05 Denso International America, Inc. Vehicle feature control systems and methods based on smoking
US11760169B2 (en) 2020-08-20 2023-09-19 Denso International America, Inc. Particulate control systems and methods for olfaction sensors
US11760170B2 (en) 2020-08-20 2023-09-19 Denso International America, Inc. Olfaction sensor preservation systems and methods
US11881093B2 (en) 2020-08-20 2024-01-23 Denso International America, Inc. Systems and methods for identifying smoking in vehicles
US11636870B2 (en) 2020-08-20 2023-04-25 Denso International America, Inc. Smoking cessation systems and methods
US12251991B2 (en) 2020-08-20 2025-03-18 Denso International America, Inc. Humidity control for olfaction sensors
US11813926B2 (en) 2020-08-20 2023-11-14 Denso International America, Inc. Binding agent and olfaction sensor
US11828210B2 (en) 2020-08-20 2023-11-28 Denso International America, Inc. Diagnostic systems and methods of vehicles using olfaction
US11932080B2 (en) 2020-08-20 2024-03-19 Denso International America, Inc. Diagnostic and recirculation control systems and methods
US12269315B2 (en) 2020-08-20 2025-04-08 Denso International America, Inc. Systems and methods for measuring and managing odor brought into rental vehicles

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
US6350458B1 (en) 1998-02-10 2002-02-26 Generex Pharmaceuticals Incorporated Mixed micellar drug deliver system and method of preparation
WO2008021542A2 (en) 2006-08-17 2008-02-21 Cell Signaling Technology, Inc. Lysine acteylation sites
CA2726734C (en) * 2007-06-06 2014-10-07 University Of Maryland, Baltimore Hdac inhibitor ms-275 and aromatase inhibitors for the treatment of cancer
WO2008154382A1 (en) 2007-06-06 2008-12-18 University Of Maryland, Baltimore Hdac inhibitors and hormone targeted drugs for the treatment of cancer
WO2009067500A1 (en) 2007-11-19 2009-05-28 Syndax Pharmaceuticals, Inc. Administration of an inhibitor of hdac
WO2012106473A2 (en) 2011-02-02 2012-08-09 Genentech, Inc. Dosing for treatment with anti-egfl7 antibodies
CA2831572C (en) 2011-05-02 2019-11-26 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
UA123212U (uk) 2011-09-02 2018-02-26 Общєство С Огранічєной Отвєтствєностью "Новамедіка" Спосіб лікування раку молочної залози
CH706458B1 (fr) 2012-04-30 2017-05-15 Granit Tech Sa Procédé de cimentation pour le stockage de déchets.

Also Published As

Publication number Publication date
UA124238U (uk) 2018-03-26
CA2847348A1 (en) 2013-03-07
JP2017149761A (ja) 2017-08-31
MX358254B (es) 2018-08-10
EP3381454A1 (en) 2018-10-03
KR101956861B1 (ko) 2019-03-12
US10226472B2 (en) 2019-03-12
JP6195384B2 (ja) 2017-09-13
CN107982270A (zh) 2018-05-04
JP2014525465A (ja) 2014-09-29
UA149007U (uk) 2021-10-13
EA201201474A1 (ru) 2013-08-30
UA123212U (uk) 2018-02-26
KR20140108629A (ko) 2014-09-12
US20140378420A1 (en) 2014-12-25
EP2751267A4 (en) 2015-01-07
BR112014005080A2 (pt) 2017-03-28
AU2012301616A1 (en) 2014-04-17
AU2018203059A1 (en) 2018-05-17
AU2012301616B2 (en) 2018-02-08
EP2751267A1 (en) 2014-07-09
ES2663407T3 (es) 2018-04-12
WO2013033656A1 (en) 2013-03-07
MX2014002515A (es) 2015-05-07
CN114053284A (zh) 2022-02-18
UA124241U (uk) 2018-03-26
US20190343844A1 (en) 2019-11-14
UA124240U (uk) 2018-03-26
GEP201706612B (en) 2017-02-10
UA124239U (uk) 2018-03-26
CN103906837A (zh) 2014-07-02
EP2751267B1 (en) 2018-01-24

Similar Documents

Publication Publication Date Title
HK1254859A1 (zh) 治疗乳腺癌的方法
KR20180043202A (ko) 암을 치료하는 방법
AU2015314753A1 (en) Human dosing of phosphatase inhibitor
IL323063A (en) Combination of a histone deacetylase inhibitor and an antibody against programmed cell death protein 1 for cancer treatment
JP6860949B2 (ja) 癌の処置方法
KR20180095586A (ko) 난소암 치료를 위한 hdac 억제제와 항-pd-l1 항체의 조합
AU2016318136A1 (en) Selection of patients for combination therapy
WO2020041466A1 (en) Platelet count-agnostic methods of treating myelofibrosis
TW202120086A (zh) 治療癌症之方法
CA2980297C (en) Combination of hdac inhibitor and anti-pd-1 antibody for treatment of cancer
RU2796903C2 (ru) Комбинация ингибитора hdac и анти-pd-1 антитела для лечения рака
UA144014U (uk) Набір для лікування стійкого до інгібітора ароматази раку молочної залози
EA043047B1 (ru) Новый способ профилактического лечения непроизвольной потери массы